Discovery US 2024

19 - 20 November 2024 | Boston, MA

Connecting experts in biology & chemistry to advance small molecule drug discovery

Event Page - Hero Banner 6

Explore Discovery US 2024: Fast-Tracking Novel Target Identification & Validation

As recent technological and pharmacological advances tackle the previously ‘undruggable’, Discovery US returns to support the discovery of novel pharmaceutical modalities beyond the rule of five – including novel degraders, molecular glues, orally-available peptides and radioligands.

The focussed, two-day agenda showcases the key platforms and technologies impacting early drug pipelines, from DNA-encoded libraries and phenotypic screening through to AI algorithms and organoid models. It brings together experts in target discovery and validation from across small & large biopharma organizations to discuss how the newest therapeutic paradigms can overcome historic challenges in drug development and provide optimized, novel drug candidates. Further sessions explore the use of automation to augment drug development and improve your lab productivity, showcasing the competitive advantages that can be gained in drug development through digitalization and robotics.

Discovery US 2024

  • Benefit from our revamped programme for 2024, designed to provide in-depth discussion of the key technologies, modalities & platforms transforming small molecule drug discovery  
  • Discover emerging drug targets beyond the rule of five, from Induced Proximity & Molecular Glues through to siRNAs and orally-available peptides, with case studies on the chemical & biological considerations of developing these complex molecules
  • Enable your lab to operate at peak productivity. Maximize your R&D capabilities with integration of advanced robotics & automation, as well as utilizing AI to augment your drug development

Agenda at a Glance

  • Day One | Track 1: Novel Targets Beyond The Rule Of Five: Degraders, Glues & Induced Proximity
  • Day One | Track 2: Innovative Technologies For Hit Identification & Screening 
  • Day One | Track 3: Novel Models For ADME-Tox Research & Disease Modelling
  • Day One | Track 4: Augmenting R&D With AI
  • Day Two | Track 1: Novel Targets Beyond The Rule Of Five: siRNAs, Radioligands, Peptides & Macrocycles
  • Day Two | Track 2: Computational & Medicinal Chemistry
  • Day Two | Track 3: Genomics-Driven Drug Discovery & Bioinformatics
  • Day Two | Track 4: Improving Lab Productivity With Robotics & Automation

What to Expect


leading pharma, biotech & academic delegates

hours of presentations, discussions & interactive content
hours of networking breaks, including speed networking & refreshments
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 75 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Discovery US 2023: 01 - 02 November 2023, Cambridge, USA

BanuPriya Sridharan
Associate Director,
Beth Hoffman
Chief Executive Officer,
Origami Therapeutics
Dane Corneil
Director of AI Science,
Benevolent AI
Eric Martin
Joe Franklin
Vice President,
Lauren Goodrich
VP, Therapeutic Discovery,
Nimble Therapeutics
Nils Hansen
Chief Executive Officer,
Thomas Nittoli
Senior Director,

All Speakers

Aaron Frank
Head of Computational Chemistry,
Arrakis Therapeutics
Abhinav Sharma
Translational Human Models Lead Engineer, Discovery Immunology,
Amir Nikooie
Eli Lilly
Andrew Doran
Principal Scientist, Automation,
Angel Guzman-Perez
Executive Vice President, Head of Chemistry,
Scorpion Therapeutics
Dave Mauger
Director of Data Science,
Arrakis Therapeutics
Elliott Nickbarg
principal scientist,
Emmanuel Bengio
Senior Machine Learning Scientist,
Recursion Pharmaceuticals
Eric Miele
Associate Director Proteomics,
Esther Lee
Associate Director, Medicinal Chemistry,
Glenn Kazo
Chief Business Officer,
ARIZ Precision Medicine
Govinda Bhisetti
Vice President,
Hasan Khan
Senior Scientist II,
Hongwu Wang
Principal Scientist,
Merck US
India Ott
Istvan Enyedy
Senior Principal Scientist,
James Hickman
Professor of NanoScience Technology,
University of Central Florida
Jason Ekert
Heas translational biology,
Jeannie Lee
Professor of Genetics,
Brigham and Women's Hospital
Jeff Messer
Director Analytics,
John Santa Maria
Associate Director of Cheminformatics,
Justyna Sikorska
Associate Principal Scientist,
Merck US
Kevin Robbins
Associate Principal Scientist,
Kingsley Appiah
Director, In Vitro Pharmacology & HTS,
Dewpoint Therapeutics
Kumar Suresh
Vice President R&D,
Progenra Inc.
Lee Herman
Director Computational Chemistry,
Sunovion Pharmaceuticals
Lucas Mastromatteo
Data Analyst,
Mark Murcko
Dewpoint Therapeutics
Martin Redhead
Executive Director Primary Pharmacology,
Matthew Pharris
Senior Scientist,
Maximilian Schuier
Senior Global Medical Affairs Leader Neuropsychiatry,
Mike Schopperle
Paul Scola
Bristol Myers squobb
Rajeswari Basu
Post Doctoral Scientist,
Stony Brook University
Ralph Mazitschek
Brigham and Women's Hospital
Shahar Keinan
Chief Executive Officer,
Shaun McLoughlin
Senior Scientist III,
Sina Mohammadi
Principal Scientist,
Merck US
Stefan Peukert
Associate Director,
Timothy Smith
Associate Director of Sales,
Tobias Raabe
Research Assistant Professor,
University of Pennsylvania
Tomasz Cierpicki
University of Michigan
Xiang Chen
Associate Member,
St Jude Children's Research Hospital
Yuan Wang
Head, Research Analytics,
Yuxin Liang
Senior Principal Scientific Manager, The NGS Lab,

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments

Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles.

Newcells Products and Services

From Screening to Success: How Molecular 'Super-Glue' SJ3149, Could Advance Cancer Treatments

Researchers at St Jude Children's Research Hospital used high throughput screening (HTS) to identify SJ3149, a molecular glue degrader. This small molecule demonstrated efficacy across a range of cancer types.

Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre

Novo Nordisk and NVIDIA join forces to build an AI supercomputer which will be housed in Denmark's national centre for AI innovation.

AI-driven High Throughput Screening for Targeted Drug Discovery

Artificial Intelligence (AI) has significantly transformed high throughput screening (HTS) in drug discovery, increasing efficiency, accuracy, and predictive capabilities in early drug development stages. This research highlights AI's integration into HTS processes, showcasing improved outcomes in hit identification, assay optimization, and target validation, thus accelerating and refining the search for new medications.

Post-Event Proceedings – Discovery Europe 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Discovery Europe 2023.

Plan Your Visit

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery US 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch